Latest Tax Incentives News

AnteoTech has marked a pivotal quarter with its first commercial Ultranode™ order shipped to Mercedes-Benz and a $4.3 million capital raise to accelerate growth in clean energy and life sciences.

Zeotech Limited has secured a strategic MOU with Holcim Australia to advance its AusPozz™ low-carbon concrete product, alongside promising methane reduction results and a newly granted Japanese patent.

IDT Australia reports a near doubling of quarterly revenue to $5.3 million, driven by explosive growth in its Advanced Therapies segment, with first-half revenue expected to jump 82%.

Dimerix Limited has inked a lucrative licensing agreement with Fuso Pharmaceutical for its kidney disease drug DMX-200 in Japan, while completing recruitment for its pivotal Phase 3 ACTION3 trial.

Entyr Limited has launched a $9.5 million capital raising via a Share Purchase Plan and Placement Offer, aiming to recapitalize and return to ASX trading following its recent voluntary administration.

Alterity Therapeutics is poised to release topline data from its pivotal ATH434-201 Phase 2 trial in early-stage Multiple System Atrophy by February 2025, while managing a cash balance of A$4.54 million amid ongoing research expenses.

Paradigm Biopharmaceuticals has secured a $6.3 million R&D Tax Incentive refund, lifting its cash reserves to $31 million and reinforcing its push into Phase 3 osteoarthritis clinical trials.

Parkway Corporate Limited reports a robust December quarter with a 420% revenue increase and key milestones in brine processing technology, positioning itself as a pivotal player in Queensland's CSG industry.

Rhythm Biosciences reported a strong December quarter, securing a $3.2 million R&D tax incentive and completing a strategic acquisition of Genetype assets, positioning the company for commercial expansion in cancer diagnostics.

Mighty Kingdom Ltd has appointed Dylan Miklashek as Interim CEO and Duncan Gordon as Non-Executive Chair, signaling a fresh leadership approach amid a company restructuring.

Hazer Group has successfully completed its Commercial Demonstration Plant program ahead of schedule, validating its methane pyrolysis technology and securing significant funding to accelerate commercialisation in 2025.

Andromeda Metals has secured a $2.34 million R&D tax refund for the 2024 financial year, reinforcing its funding strategy and underpinning development of the Great White Project.